Zhongzhi Pharmaceutical Holdings Limited provided consolidated earnings guidance for the six months ended June 30, 2025. The Board informed the shareholders of the company and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025, a decrease in net profit of around 90% for the six months ended 30 June 2025 are expected as compared to those for the six months ended 30 June 2024. In 2025, due to the adjustment of industry policies, sales revenue dropped in the short term and profit was affected to a certain extent.
The Group will maintain its efforts in market investment and actively explore new business growth points.
